Human immunodeficiency virus (HIV) affects millions of children worldwide. New pediatric cases are continuing to be diagnosed. However, with the approval and use of various new protocols and antiretroviral agents, transmission rates in perinatally exposed infants have dramatically declined and survival of HIV-infected children has been prolonged. Prevention education is the starting point to try to reduce future transmission; however, increases in HIV cases continue to be seen in the adolescent population. Current pharmacological therapy of HIV includes a multidrug regimen with the potential for numerous drug-drug interactions, adverse effects, and development of resistance. Routine monitoring of adherence is required to try to attain and sustain viral suppression. This review will focus on current treatment recommendations for infants, children, and adolescents infected with HIV, including newly approved agents in 2003. Pediatric considerations, including differences in diagnosis and monitoring, will also be discussed.
Global summary of the HIV/AIDS epidemic. December 2003. Available at: http://www.unaids.org/wad/2003/Epiupdate2003_en/Epi03_02_en.htm.
2.
National Center for HIV, STD and TB Prevention. Divisions of HIV/AIDS Prevention. Estimated numbers of diagnoses of AIDS in children < 13 years of age, by year of diagnosis and exposure category. United States. 1998-2002. Available at: http://www.cdc.gov/hiv/stats/hasr1402/table4.htm.
3.
Joint United Nations Programme on HIV/AIDS. Report on the global HIV/AIDS epidemic 2002. Available at: http://www.unaids.org/en/resources/epidemiology.asp.
4.
National Center for HIV, STD and TB Prevention. Divisions of HIV/AIDS Prevention. Estimated numbers of persons living with HIV infection (not AIDS) or with AIDS at the end of 2002. United States. Available at: http://www.cdc.gov/hiv/stats/hasr1402/table12.htm.
5.
National Institutes of Health. National Institute of Allergy and Infectious Disease fact sheet. December 2000. Available at: http://www.aidsinfo.org.
6.
National Center for HIV, STD and TB Prevention. Divisions of HIV/AIDS Prevention. Estimated numbers of deaths of persons with AIDS. United States. 1998-2002. Available at: http://www.cdc.gov/hiv/stats/hasr1402/table7.htm.
Salvatori F.Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease. J Virology. 1997;71:4694-4706.
9.
Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. November 26, 2003. Available at: http://AIDSinfo.nih.gov.
10.
Mofenson LM. Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. Acta Paediatr Suppl. 1997;421:1-9.
11.
Centers for Disease Control. Revised recommendations for HIV screening of pregnant women: perinatal counseling and guidelines consultation. MMWR Morb Mortal Wkly Rep. 2001;50:59-86.
12.
Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-1180.
13.
Rodman JH, Robbins BL, Flynn PM, Fridland A.A systemic and cellular model for zidovudine plasma concentrations and intracellular phosphorylation in patients. J Infect Dis. 1996;174:490-494.
14.
Mulder JW, Cooper DA, Mathiesen L, et al. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind, placebo-controlled study. AIDS. 1994;8:313-321.
15.
Shaffer N, Bulterys M, Simonds RJ. Short courses of zidovudine and perinatal transmission of HIV. N Engl J Med. 1999;340:1042-1043.
16.
Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859-868.
17.
1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep. 1994;43:1-10.
18.
The Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection and pediatric antiretroviral drug information supplement. January 20, 2004. Available at: http://AIDSinfo.nih.gov.
19.
Palumbo P, Burchett S.Diagnosis of HIV infection and markers of disease progression in infants and children. In: Pizzo PA and Wilfert CM, eds. Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents. 3rd ed.Philadelphia, Pa: Lippincott Williams & Wilkins; 1998:67-87.
20.
US Public Health Service and Infectious Diseases Society of America. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. November 28, 2001. Available at: http://AIDSinfo.nih.gov.
21.
Department of Health and Human Services. Division of AIDS, National Institute of Allergy and Infectious Disease, National Institute of Health. Interim results from AACTG protocol A5095. March 10, 2003. Available at: http://www.niaid.nih.gov/daids/pdf/aactg_a5095.pdf.
22.
Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. March 23, 2004. Available at: http://www.AIDSinfo.nih.gov.
23.
Romanelli F, Pomeroy C.Human immunodeficiency virus drug resistance testing: state of the art in genotypic and phenotypic testing of antiretrovirals. Pharmacotherapy. 2000;20:151-157.
24.
Brinkman K.Mitochondrial toxicities of nucleoside reverse transcriptase inhibitors. The PRN Notebook. 2000;5:18-22.
25.
Church JA, Mitchell WG, Gonzalez-Gomez I, et al. Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr. 2001;138:748-751.
26.
Mallal SA. Mitochondrial toxicity. HIV/AIDS Update. 2002. Available at: http://www.medscape.com/viewarticle/441841.
27.
Ziagen [package insert]. Research Triangle Park, NC: GlaxoSmithKline; April 2004.
28.
Knupp CA, Milbrath R, Barbhaiya RH. Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation. J Clin Pharmacol. 1993;33:568-573.
29.
Videx [package insert]. Princeton, NJ: Bristol-Myers Squibb; January 2004.
30.
Viread [package insert]. Foster City, Calif: Gilead Sciences; August 2003.
31.
Emtriva [package insert]. Foster City, Calif: Gilead Sciences; July 2003.
32.
Epivir [package insert]. Research Triangle Park, NC: GlaxoSmithKline; September 2003.
33.
Perry CM, Faulds D.Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs. 1997;53:657-680.
34.
Lewis LL, Venzon D, Church J, et al. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. J Infect Dis. 1996;174:16-25.
35.
Zerit [package insert]. Princeton, NJ: Bristol-Myers Squibb; April 2002.
36.
Lea AP, Faulds D.Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs. 1996;51:846-864.
37.
Hivid [package insert]. Nutley, NJ: Roche Pharmaceuticals; September 2002.
38.
Retrovir [package insert]. Research Triangle Park, NC: GlaxoSmithKline; April 2003.
39.
Epivir-HBV [package insert]. Research Triangle Park, NC: GlaxoSmithKline; September 2003.
40.
Rescriptor [package insert]. La Jolla, CA: Agouron Pharmaceuticals; June 2001.
41.
Sustiva [package insert]. Princeton, NJ: Bristol-Myers Squibb; June 2003.
42.
Collura JM, Kraus DM. New pediatric antiretroviral agents. J Pediatr Health Care. 2000;14:183-192.
43.
Viramune [package insert]. Ridgefield, Conn: Boehringer Ingelheim Pharmaceuticals; January 2004.
Agenerase [package insert]. Research Triangle Park, NC: GlaxoSmithKline; February 2004.
46.
Reyataz [package insert]. Princeton, NJ: Bristol-Myers Squibb; March 2004.
47.
Lexiva [package insert]. Research Triangle Park, NC: GlaxoSmithKline; October 2003.
48.
Crixivan [package insert]. Whitehouse Station, NJ: Merck; January 2004.
49.
Kaletra [package insert]. North Chicago, Ill: Abbott Laboratories; December 2003.
50.
Viracept [package insert]. La Jolla, Calif: Agouron Pharmaceuticals; March 2004.
51.
Norvir [package insert]. North Chicago, Ill: Abbott Laboratories; October 2003.
52.
Fortovase [package insert]. Nutley, NJ: Roche Laboratories; December 2003.
53.
Invirase [package insert]. Nutley, NJ: Roche Laboratories; December 2003.
54.
Gulick RM. New antiretroviral drugs. Clin Microbiol Infect. 2003;9:186-193.
55.
Fuzeon [package insert]. Nutley, NJ: Roche Pharmaceuticals; March 2003.
56.
Byrne M, Honig J, Jurgrau A, Heffernan SM, Donahue MC. Achieving adherence with antiretroviral medications for pediatric HIV disease. AIDS Read. 2002;12:151-164.
Andrews L, Friedland G.Progress in HIV therapeutics and the challenges of adherence to antiretroviral therapy. Infect Dis Clin North Am. 2000;14:901-928.
59.
Van Dyke RB, Lee S, Johnson GM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;109(4):e61-e61. Available at: http://www.pediatrics.org/cgi/content/full/109/4/e61.
60.
American Academy of Pediatrics, Committee on Pediatric Aids. Disclosure of illness status to children and adolescents with HIV infection. Pediatrics. 1999;103:164-166.
61.
Centers for Disease Control and Prevention. Young people at risk: HIV/AIDS among America’s youth. Available at: http://www.cdc.gov/hiv/pubs/facts/youth.htm.
62.
Centers for Disease Control and Prevention. Incorporating HIV prevention into the medical care of persons living with HIV. MMWR Morb Mortal Wkly Rep. 2003;52:1-24.
63.
The Hopkins HIV Report September 2003. Focusing on “prevention in positives”. Available at: http://www.hopkins-aids.edu/publications/report/sept03_5.html.
64.
People v. Jensen, 231 Mich. App. 439, 586 N.W.2d 748 (Mich. App., Aug 28, 1998). Available at: http://biotech.law.lsu.edu/cases/reporting/People_v_Jensen.htm.
65.
Watson L, Bond C, Gault C.A survey of community pharmacists on prevention of HIV and hepatitis B and C: current practice and attitudes in Grampian. J Public Health Med. 2003;25:13-18.
